scholarly journals SO004PATHOGENIC ROLE OF ANTI−HLA ANTIBODIES ON ENDOTHELIAL PROGENITOR CELL DYSFUNCTION IN HIGHLY SENSITIZED KIDNEY TRANSPLANT RECIPIENTS

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i2-i2
Author(s):  
Vincenzo Cantaluppi ◽  
Davide Medica ◽  
Giuliana Tognarelli ◽  
Marco Quaglia ◽  
Claudio Musetti ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Endothelial Progenitor Cell ◽  
Progenitor Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Endothelial Progenitor ◽  
Hla Antibodies ◽  
Cell Dysfunction

Role of microparticles as microrna messengers in reestablishing of atherosclerosis-associated endothelial progenitor cell dysfunction

2017 ◽  
Vol 263 ◽  
pp. e33
Author(s):  
Nicoleta Alexandru ◽  
Emanuel Dragan ◽  
Violeta Ristoiu ◽  
Loredan Niculescu ◽  
Adriana Georgescu
Keyword(s):  
Endothelial Progenitor Cell ◽  
Progenitor Cell ◽  
Endothelial Progenitor ◽  
Cell Dysfunction

scholarly journals Role of Inflammation and Insulin Resistance in Endothelial Progenitor Cell Dysfunction

Diabetes ◽  
2011 ◽  
Vol 60 (4) ◽  
pp. 1286-1294 ◽  
Author(s):  
C. V. Desouza ◽  
F. G. Hamel ◽  
K. Bidasee ◽  
K. O'Connell
Keyword(s):  
Insulin Resistance ◽  
Endothelial Progenitor Cell ◽  
Progenitor Cell ◽  
Endothelial Progenitor ◽  
Cell Dysfunction

P101 Development of C1Q binding donor specific anti-HLA antibodies in pediatric kidney transplant recipients

2017 ◽  
Vol 78 ◽  
pp. 127
Author(s):  
Adriana I. Colovai ◽  
Christina Savchik ◽  
Dianne Ramkishun ◽  
Sonia Solomon ◽  
Enver Akalin ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hla Antibodies

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Sign in / Sign up

Export Citation Format

Share Document